Behzad Aghazadeh - Sep 22, 2022 Form 4 Insider Report for Aadi Bioscience, Inc. (AADI)

Role
Director, Other*, 10%+ Owner
Signature
Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Financial Officer
Stock symbol
AADI
Transactions as of
Sep 22, 2022
Transactions value $
$15,750,000
Form type
4
Date filed
9/26/2022, 05:46 PM
Previous filing
Jun 17, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AADI Common Stock, $0.0001 par value per share ("Common Stock") Award $15.8M +1.26M +56.97% $12.50 3.47M Sep 22, 2022 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures (as defined below) directly from the Issuer in a private placement.
F2 This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures.
F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Remarks:

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.